论文部分内容阅读
目的:对比瑞舒伐他汀、阿托伐他汀治疗早发冠心病急性心肌梗死的临床疗效。方法:选取2013年8月—2016年9月98例早发冠心病急性心肌梗死患者,随机分组,观察组(n=49)给予瑞舒伐他汀,对照组(n=49)采用阿托伐他汀,对比2组患者临床治疗效果。结果:观察组临床总有效率为91.84%,对照组为93.88%,组间无显著差异(P>0.05);观察组治疗后hs-CRP、TC值改善程度优于对照组治疗后,组间差异显著(P<0.05)。结论:瑞舒伐他汀、阿托伐他汀均能有效治疗早发冠心病急性心肌梗死,但是在改善C反应蛋白、血清总胆固醇上临床效果更佳,值得临床推广。
Objective: To compare the clinical efficacy of rosuvastatin and atorvastatin in the treatment of acute myocardial infarction with premature coronary heart disease. Methods: From August 2013 to September 2016, 98 patients with acute myocardial infarction with premature coronary artery disease were randomly divided into two groups: rosuvastatin (n = 49) and control group (n = 49) Statin, compared with two groups of patients with clinical treatment. Results: The total clinical effective rate was 91.84% in the observation group and 93.88% in the control group. There was no significant difference between the two groups (P> 0.05). After treatment, the improvement rate of hs-CRP and TC in the observation group was better than that in the control group The difference was significant (P <0.05). Conclusion: Both rosuvastatin and atorvastatin can effectively treat acute myocardial infarction in patients with premature coronary heart disease. However, it is clinically effective in improving C - reactive protein and serum total cholesterol.